MOHSEN BEHESHTI MD - 2018ijcc.iha.org.ir2018ijcc.iha.org.ir/Files/7/Content/Dr_ Beheshti CV(2).pdf · curriculum vitae mohsen beheshti md febnm, fasnc phone +43 732 7677 7074 •

1

CURRICULUM VITAE

M O H S E N B E H E S H T I M D F E B N M , F A S N C

PHONE +43 732 7677 7074 • FAX +43 732 7677 7090 • MOBILE +43 699 1200 1504

E-MAIL [email protected]

HEAD PET – CT CENTER LINZ

D E P A R T M E N T O F N U C L E A R M E D I C I N E A N D E N D O C R I N O L O G Y

ST. VINCENT’S HOSPITAL LINZ • SEILERSTAETTE 4 • A-4010, LINZ • AUSTRIA

Ordensklinikum, Barmherzige Schwestern Linz

Lehrkrankenhaus der Medizinischen Universitäten Wien | Innsbruck | Graz

Zentrum für Tumorerkrankungen | Onkologisches Leitspital für Oberösterreich

Kopf Hals | Schilddrüse | Mamma | Pankreas | Colorectal | Gynäkologie | Prostata | PETCT

PERSONAL INFORMATION

Date of Birth: 11 September 1968

Married – 2 children

LANGUAGES

English | German | Farsi (Persian)

2

D I P L O M A | C E R T I F I C A T I N S | T R A I N I N G | M E D I C I N E

2008 - Certificate of full Specialist Registration & License to Practice GMC | General Medical Council UK

2007 Certification of PET | Deutsche Gesellschaft für Nuklearmedizin (DGN) Germany

2005 Austrian Certification Board of Nuclear Medicine | Facharztdiplom Nuklearmedizin

Österreichische Ärztekammer ÖAK

2005 Doctor Medicinae Universae (Dr. Med. Univ.) | Medical University of Innsbruck AUSTRIA

2004 Diploma in the subspecialty of Nuclear Cardiology | American Certification Board of Nuclear Cardiology

2004 Certification in Nuclear Cardiology | European Council of Nuclear Cardiology

1998 Certificate of General Medicine & Permanent License to Practice | Iranian Ministry of Health and

Education

1998 Diploma of Completion of Medical Studies (M.D.) | Iran University of Medical Sciences

A C A D E M I C T I T L E S | F E L L O W S H I P S | M E D I C I N E

2016 Associate Professor of Nuclear Medicine | Medical University of Salzburg AUSTRIA

2016 Visitig Professor | Shahid Beheshti University of Medical Sciences, Tehran, Iran

2009 FEBNM Fellowship | European Board of Nuclear Medicine

2009 FASNC Fellowship | American Society of Nuclear Cardiology

2009 Habilitation in Nuclear Medicine – Venia Docendi | Medical University of Salzburg AUSTRIA

PROFESSIONAL EXPERIENCE | L E I T U N G S F U N K T I O N E N | M E D I C I N E

2013 - Head | PET – CT Center Linz | St. Vincent’s Hospital

2006 - 2012 PET - CT Instructor | PET - CT Center LINZ, St. Vincent’s Hospital, Austria

2005 - 2012 Oberarzt Nuklearmedizin | St. Vincent’s Hospital Linz

P R O F E S S I O N A L A C T I V I T I E S | V E R A N T W O R T L I C H E P O S I T I O N E N

2015 Member of organising & scientific committee | OGNMB Congress Zell am See

2013 - EANM | European Association of Nuclear Medicine | Member Oncology Committee

2013 - OGNMB| Österreichische Gesellschaft für Nuklearmedizin & Molekulare Bildgebung |

Arbeitsgruppe PET – CT

2013 - General Secretary | Iranian Ministry of Health | National Strategic PET-CT Committee

2011 Organizer | Thyroid Cancer – Diagnosis & Therapy | St. Vincent’s Hospital, Austria

3

O R G A N I S A T O R I S C H E M E I L E N S T E I N E | L I N Z

2012 1. PET – CT 128 slice | ÖSTERREICH

2011 1. Nuklearmedizinische Therapiestation | Oberösterreich

2010 1. zertifiziertes Schilddrüsen ZENTRUM | ÖSTERREICH

A D V I S O R Y B O A R D S | M E D I Z I N

2015 - Global Advisory Board PIRAMAL | Prostate Cancer

2011 - Scientific Advisory Board GE | PET – CT

2005 - 2012 European Advisory Board IASON | Prostate & Thyroid Cancer

E D I T O R I A L B O A R D S | M E D I Z I N

2011 AJNMMI | American Journal of Nuclear Medicine & Molecular Imaging 2,52 IF (Impact Factor)

2006 IRJNM | Iranian Journal of Nuclear Medicine

AWARDS

2010 Best scientific paper, “Mallinckrodt” price | Austrian Society of Nuclear Medicine & Molecular Imaging

2008 Highlight Lecture selection SNM, New Orleans, LA| American Society of Nuclear Medicine

2006 Highlight Lecture selection SNM, San Diego, CA | American Society of Nuclear Medicine

2006 Highlight Lecture selection EANM, Athens | European Association of Nuclear Medicine

2003 Highlight Lecture selection EANM, Amsterdam | European Association of Nuclear Medicine

I N S T I T U T I O N A L C E R T I F I C A T I N S | Z E R T I F I Z I E R U N G E N

2013 European Accreditation EARL FDG PET - CT | EANM Research 4 Life Vienna

2013 Zertifizierung Onkologisches ZENTRUM Linz | Deutsche Krebsgesellschaft (DKG) Germany

2012 Zertifizierung PETCT ZENTRUM & Nuklearmedizin & Therapiestation EN ISO 9001 : 2008 |

proCum Cert Germany

2010 Zertifizierung Schilddrüsen ZENTRUM Linz EN ISO 9001 : 2008 | proCum Cert Germany

2009 Zertifizierung PET – CT Zentrum & Nuklearmedizin & RIA Labor EN ISO 9001 : 2008 | Quality

Austria

4

E D U C A T I N A L A C T I V I T I E S | L E H R & P R Ü F U N G S T Ä T I K E I T E N

2016 - Sh. Beheshti Medical University, Iran | Invited Scientific Staff

2010 - Medizinische Universität SALZBURG | Spezial Vorlesungen Nuklearmedizin & Endokrinologie

ADDITIONAL PROFESSIONAL ACTIVITIES

2005- Scientific collaborator | Department of Nuclear Medicine & Endocrinology | Medical University of

Salzburg AUSTRIA

2004 - Scientific collaborator | Department of Nuclear Medicine, Medical University of Vienna AUSTRIA

P R O F E S S I O N A L M E M B E R S H I P S I N T E R N A T I O N A L

2005 - The Society of Nuclear Medicine of North America (SNM)

2004 - American Society of Nuclear Cardiology (ASNC)

2004 - Iranian Society of Nuclear Medicine (ISNM)

2002 - European Association of Nuclear Medicine (EANM)

1998 - Iranian General Medical Council (IR. GMC)

P R O F E S S I O N A L M E M B E R S H I P S N A T I O N A L

2004 - Austrian Society of Nuclear Medicine & Molecular Imaging (OGNMB)

2001 - Austrian Medical Council | Österreichische Ärztekammer ÖAK

F U N D S | D R I T T M I T T E L A K Q U I S I T I O N E N | L I N Z

2014 - 2015 PIRAMAL Grant | PET – CT Center Linz 250.000,00 EUR

2011 – 2012 BAYER Grant | PET – CT Center Linz 250.000,00 EUR

RESEARCH POSITIONS

Principle - Investigator

2014 Phase I study:

Open-label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of

safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 in patients with primary prostate cancer

5

2014 Phase II study:

18F – Choline PET – CT in the assessment of parathyroid adenoma: A novel tracer

2011 Phase II - III study:

Detection and Quantification of Cardiovascular Molecular Calcification by 18F - Flouride PET CT: A Novel Approach

for Studying Atherosclerosis

2011 Phase I study:

Open - label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of

safety, tolerability, biodistribution and diagnostic performance of the 18F labeled PET tracer BAY 1075553 in healthy

volunteers

2009 Phase II study:

[18F]Fluoride PET/CT vs. 99mTc – MDP Scanning for Detecting Bone Metastases: A Randomized, Multi – Center Trial

to Compare Two Bone Imaging Techniques

REFERENCES

Prof. Abass Alavi University of Pennsylvania, USA

Prof. Ignas Fogelman Kings College London, UK

Prof. Werner Langsteger St. Vincent’s Hospital Linz, Austria

6

PUBLICATIONS – PEER REVIEWD

2016

1. Beheshti M, Rezaee A, Loidl W, Geinitz H, Langsteger W.

Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-choline PET/CT

Journal of Nuclear Medicine, Prostate Cancer Supplement, Review, 2016 under publication

2. Beheshti M, Rezaee A, Langsteger W.

MDP and Fluoride for detection of bone metastases in prostate cancer

Seminars in Nuclear Medicine, Review, 2016 under publication

2015

3. Spick C, Polanec SH, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas

G.

Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.

Anticancer Res. 2015 Dec;35(12):6787-91.

4. Haroon A, Zanoni L, Celli M, Zakavi R, Beheshti M, Langsteger W, Fanti S, Emberton M, Bomanji J.

Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male

patients: physiological distribution, statistical differences, imaging pearls, and normal variants.

Nucl Med Commun. 2015 Nov;36(11):1065-75. doi: 10.1097/MNM.0000000000000372.

5. Beheshti M, Mottaghy FM, Payche F, Behrendt FF, Van den Wyngaert T, Fogelman I, Strobel K, Celli M, Fanti S,

Giammarile F, Krause B, Langsteger W.

(18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1767-77. doi: 10.1007/s00259-015-3138-y. Epub 2015 Jul 23.

6. Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M.

Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):96-108. eCollection 2015. Review.

2014

7. Bitarafan-Rajabi A, Rajabi H, Rastgou F, Firoozabady H, Yaghoobi N, Malek H, Langesteger W, Beheshti M.

Influence of respiratory motion correction on quantification of myocardial perfusion SPECT.

J Nucl Cardiol. 2015 Oct;22(5):1019-30. doi: 10.1007/s12350-014-0031-1. Epub 2014 Dec 17.

8. Beheshti M, Kunit T, Haim S, Zakavi R, Schiller C, Stephens A, Dinkelborg L, Langsteger W, Loidl W.

BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with 18F-Choline PET-CT

(Phase I Study)

7

American Journal of Molecular Imaging & Biology. 2014 September.

9. Kim CK, Beheshti M.

PET Tracers Beyond FDG: Normal Variations and Benign Findings.

PET Clin. 2014 Jul;9(3):xi-xii. doi: 10.1016/j.cpet.2014.04.001.

10. Karanikas G, Beheshti M.

11C-Acetate PET/CT Imaging: Physiologic Uptake, Variants, and Pitfalls.

PET Clin. 2014 Jul;9(3):339-344. doi: 10.1016/j.cpet.2014.03.006. Epub 2014 May 3. Review.

11. Beheshti M, Haroon A, Bomanji JB, Langsteger W.

Fluorocholine PET/Computed Tomography: Physiologic Uptake, Benign Findings, and Pitfalls.

PET Clin. 2014 Jul;9(3):299-306. doi: 10.1016/j.cpet.2014.03.001. Epub 2014 Apr 22. Review.

12. Beheshti M, Kim CK.

FDG PET/CT: Normal Variations and Benign Findings - Translation to PET/MRI.

PET Clin. 2014 Apr;9(2):xiii-xiv. doi: 10.1016/j.cpet.2014.02.001.

13. Pirich C, Keinrath P, Rettenbacher L, Rendl G, Holzmannhofer J, Hammerer M, Schuler J, Beheshti M.

99mTc tetrofosmin myocardial perfusion scintigraphy in CAD. Performance with early and standard delayed acquisition

and fractional flow reserve.

Nuklearmedizin. 2014 Jun 25;53(3):111-6. doi: 10.3413/Nukmed-0617-13-08.

2013

14. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.

Impact of 18F Choline PET/CT in prostate cancer patients with biochemical recurrence - influence of androgen

deprivation therapy and correlation with PSA kinetics.

J Nucl Med, Jun;54(6):833-40. doi: 10.2967/jnumed.112.110148. Epub 2013 Apr 4. (6,381) TOP

15. Langsteger W, Beheshti M.

Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best.

Eur J Nucl Med Mol Imaging 2013 Sep;40(9):1438-61 (5,036) TOP

8

2012

16. Berger C, Becker T, Koen M, Zeino M, Fitz F, Beheshti M, Wolf – Kohlmeier I, Haim S, Riccabona M. Positioning

irrigation of contrast cystography for diagnosis of occult vesicoureteric reflux: Association with technetium-99m

dimercaptosuccinic acid scans.

J Pediatr Urol 2012, 12, 1 – 5 (1,379)

17. Langsteger W, Haim S, Knauer M, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M.

Imaging in Bone Metastases: An Update.

Q J Nucl Med Mol Imaging 2012, 56:447 - 58 (2,537) STANDARD

18. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I.

18F – Fluorocholine for Prostate Cancer Imaging: A Systematic Review of the Literature.

Prostate Cancer Prostatic Dis 2012, 15:45 – 55 (2,263) STANDARD

19. Traub – Weidinger T, Graf S, Beheshti M, Ofluoglu S, Zettinig G, Khorsand A, Nekolla SG, Kletter K, Dudczak R,

Pirich C.

Coronary Vasoreactivity in Subjects with Thyroid Autoimmunity and Subclinical Hypothyroidism

Before and After Supplementation with Thyroxine.

Thyroid 2012, 22:245 - 251 (4,327) TOP

20. Rubello D, Wong KK, Marzola MC, Beheshti M, Ambrosini V, Chondrogiannis S, Gross MD.

Editorial Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.

Eur J Nucl Med Mol Imaging 2012, 39:563 - 8 (5,036) TOP

21. Beheshti M, Langsteger W.

Choline PET – CT Compared With Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer

Patients (Letter)


2011

22. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K,

Pascal O, Cussenot O, Talbot JN.

Fluorocholine (18F) and Sodium Fluoride (18F) PET – CT in the Detection of Prostate Cancer: Prospective

Comparison of Diagnostic Performance Determined by Masked Reading.

Q J Nucl Med Mol Imaging 2011, Aug;55:448 - 457 (2,537) STANDARD

23. Beheshti M, Saboury B, Mehta NN, Torigian DA, Werner T, Mohler E, Wilensky R, Newberg AB, Basu S, Langsteger

W, Alavi A.

9

Detection and Global Quantification of Cardiovascular Molecular Calcification by Fluoro18 - Fluoride Positron

Emission Tomography/Computed Tomography - A Novel Concept.

Hell J Nucl Med 2011, 14(2):114-20 (0,710) STANDARD

24. Nader M, Reindl D, Eichinger R, Beheshti M, Langsteger W.

Improved quality control of [18F]fluoromethylcholine

Nucl Med Biol 2011, 38:1143 – 8 (3,023) TOP

2010

25. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger

W.

F – 18 Choline PET in the Preoperative Staging of Prostate Cancer Patients with Intermediate and High Risk of Extra

– Capsular Disease: A Prospective Study in 130 Patients.

Radiology 2010, 254:925 - 933 (6,069) TOP

26. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W.

The Use of F – 18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with

Morphological Changes on CT.

Mol Imaging Biol 2010, 12:98 - 107 (3,139) TOP

27. Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W.

Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected

metastatic recurrence of breast cancer.

Eur J Radiol 2010, 73:294 - 9 (3,589) TOP

28. Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W.

Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer:

Comparison with PET and enhanced CT.

Eur J Radiol 2010, 73:324 - 8 (3,589) TOP

2009

29. Beheshti M, Langsteger W, Fogelman I.

Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases.

Semin Nucl Med 2009, 39:396 - 407 (4,534) TOP

30. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W.

10

The Value of F – 18 DOPA PET – CT in Patients with Medullary Thyroid Carcinoma: Comparison with F – 18 FDG

PET – CT.

Eur Radiol 2009, 19:1425 - 1434 (3,589) TOP

31. Kohlfürst S, Igerc I, Lobing M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, Mayr J, Mikosch P, Beheshti M, Lind

P.

I 131 posttherapeutic SPECT-CT offers a diagnostic accuracy in case of in conclusive findings in conventional planar

imaging and allows a tailored patient treatment regimen.

Eur J Nucl Med Mol I 2009, 36:886 - 93 (5,036) TOP

2008

32. Bitarafan – Rajabi A, Rajabi H, Gruy B, Rustgou F, Sharafi AA, Firoozabady H, Yaghoobi N, Malek H, Pirich C,

Langsteger W, Beheshti M.

Respiratory Motion Detection and Correction in ECG – Gated SPECT: A New Approach.

Korean J Radiol 2008, 9:490 - 497 (1,766) STANDARD

33. Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, Dirisamer F, Weber M, Langsteger W.

Dual – Time – Point FDG PET – CT for the Detection of Hepatic Metastases.

Mol Imaging Biol 2008, 10:335 - 340 (3,139) TOP

34. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Fogelman I, Langsteger W.

Detection of Bone Metastases in Patients with Prostate Cancer by F – 18 Fluorocholine and F – 18 Fluoride PET –

CT: A Comparative Study.

Eur J Nucl Med Mol I 2008, 35(10):1766 - 1774 (5,036) TOP


PET – CT for Monitoring Therapy Response in Breast Cancer Patients with Bone Metastases (Letter)

Radiology 2008, 249:389 - 90 (6,069) TOP

2007

36. Beheshti M, Li S, Vali R, Schima W, Dudczak R, Langsteger W.

The Potential Value of F – 18 FDG PET in Comparison to CT in Early Prediction of Response to Imatinib (STI571)

Therapy in Patients with Gastrointestinal Stromal Tumors.

Iran J Nucl Med 2007, 15:34 - 42 not listed

37. Beheshti M, Vali R, Langsteger W.

18 - F Fluorcholine PET CT in the Assessment of Bone Metastases in Prostate Cancer (Letter)

11


2006

38. Li S, Beheshti M, Peck-Radosavljevic M, Oezer S, Grumbeck E, Schmid M, Hamilton G, Kapiotis S, Dudczak R, Kletter

K.

Comparison of (11)C - Acetate Positron Emission Tomography and (67)Gallium Citrate Scintigraphy in Patients with

Hepatocellular Carcinoma.

Liver Int 2006, 26:920 - 7 (3,84) TOP

39. Schuetz M, Beheshti M, Oezer S, Novotny C, Paul M, Hofmann A, Bieglmayer C, Niederle B, Kletter K, Dudczak R,

Karanikas G, Pirich C. Calcitoninmeasurements for early detection of medullary thyroid carcinoma or its premalignant

conditions in Hashimoto's thyroiditis.

Anticancer Res 2006, 26:723 - 7 (1,656) STANDARD

40. Beheshti M, Khorsand A, Graf S, Dobrozemsky G, Oezer S, Kletter K, Dudczak R, Pirich C.

FDG gamma camera PET equipped with one inch crystal and XCT. Assessment of myocardial viability.

Nuklearmedizin 2006, 45:163 - 70 (1,752) STANDARD

2005

41. Li S, Beheshti M.

The radionuclide molecular imaging and therapy of neuroendocrine tumors.

Curr Cancer Drug Target 2005, 5:139 - 48 (4,771) TOP

2004

42. Ozer S, Dobrozemsky G, Kienast O, Beheshti M, Becherer A, Niederle B, Kainberger F, Dudczak R, Kurtaran A.

Value of combined XCT/SPECT technology for avoiding false positive planar 123)I-MIBG scintigraphy.

Nuklearmedizin 2004, 43:164 - 70 (1,752) STANDARD

43. Li S, Peck-Radosavljevic M, Kienast O, Preitfellner J, Havlik E, Schima W, Traub-Weidinger T, Graf S, Beheshti M,

Schmid M, Angelberger P, Dudczak R.

Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in

patients with pancreatic carcinoma.

Q J Nucl Med Mol Imaging 2004, 48:198 - 206 (2,537) STANDARD

44. Pirich C, Graf S, Beheshti M.

Diagnostic and Prognostic Impact of Nuclear Cardiology in the Management of Acute Coronary Syndromes and Acute

Myocardial Infarction.

12

Imaging Decisions 2004, 8:9 - 16 not listed

2003

45. Beheshti M, Graf S, Pirich C.

Myocardial Perfusion Imaging.

Imaging Decisions 2003, 7:29 - 35 not listed

13

BOOK | CHAPTERS

2016


PET/CT in Cancer: An Interdisciplinary approach to individualized Imaging

Editor, Published by Elsevier


Bone Metastases from Prostate Cancer

In Editing Bombardieri, Bertoldo, Boccardo, Evangelista and Valdagni, 2016 Under Edition

3. Beheshti M, Haim S, Langsteger W.

PET - CT in der Diagnostik des Prostatakarzinoms

Prostata: Multimodale Bildgebung, Breitenseher Publisher, January 2016

4. Langsteger W, Vali R, Beheshti M.

Prostate Cancer

Molecular Anatomic Imaging, Wolters Kluwer, 2016

5. Beheshti M, Langsteger W, Löfgern J, Pirich C.

PET – CT, Tracers beyond FDG: Case study

Nuclear Medicine: A Case – Based Approach, Jaypee, 2016

2015

6. Beheshti M, Haim S, Langsteger W.

Nulklearmedizin der Prostata und aeusseren Genitalia

Die Urologie, Springer-Verlag Heidelberg, 2015-16

7. Haim S, Beheshti M, Langsteger W.

Nuklearmedizinische Verfahren der Niere, des Retroperitoneums und der Harnblase

Die Urologie, Springer-Verlag Heidelberg, 2015-16

2014

8. Kim C, Beheshti M (Editors)

PET/CT Imaging in Tracers beyond FDG: Normal Variations & Benign findings

PET Clinics, Elsevier, July 2014

14


Choline PET/CT: Normal Variations & Benign findings

10. Beheshti M, Kim C (Editors)

FDG PET/CT Imaging Normal Variations & Benign findings: translation to PET/MRI

PET Clinics, Elsevier, April 2014

2012


F – 18 NaF PET – CT in the Assessment of Metastatic Bone Disease: Comparison with Specific PET Tracers.

In Beheshti M (Editor), PET Clinics 2012


Prostate Cancer: Role of Conventional Radionuclide and Hybrid Bone Imaging.

In Fogelmann I (Editor), Springer 2012

2009


PET Imaging of Prostate Cancer Using Radiolabeled Choline

In Jadvar H, Alavi A (eds) PET Clinics 2009 Molecular Imaging of Prostate Cancer. WB Saunders Company

Philadelphia pp 173 – 184, 2009

2007

14. Langsteger W, Beheshti M, Vali R, Beri A, Nader M, Janetschek G.

Prostate Cancer

In Bombardieri E, Buscombe J, Lucignani G, Schober O (eds) Advances in Nuclear Oncology: Diagnosis

and Therapy

Informa Healthcare London, pp109 – 131, 2007

1999

15. Beheshti M, Aroumandi H. Translation to Persian. In Otmer O, Otmer S: The clinical interview using DSM. IV.

Arjmand Publication ISBN 964-6095-51-8, published date: 1999

15

LECTURES

2016

1. Austrian Society of Nuclear Medicine & Molecular Imaging, 32nd International Symposium, Zell am See, Austria,

January 2016

Value of FDG PET CT in the initial staging of breast cancer in patients with high risk disease

2. Iranian Heart Association, 3rd International Joint Congress, Tehran, Iran, March 2016

Invited speaker: Cardiovascular Molecular Imaging: Future Trends


Invited speaker: CT Coronary Angiography (CTCA) versus Myocardial Perfusion SPECT Imaging (MPI), When to Use

Them?


Invited speaker: CT Coronary Angiography (CTCA) versus Myocardial Perfusion SPECT Imaging (MPI), When to Use

Them?

2015

5. Österreich – Bayerischer Röntgenkongress 15th, Salzburg, Austria, October 2015

Invited speaker: PET-CT Imaging in the Diagnosis of Prostate Cancer

6. European Association of Nuclear Medicine; annual meeting, Hamburg, Germany, October 2015

Value of 18F Choline PET-CT in the assessment of primary hyperparathyroidism comparing with 99mTC-Sestamibi

SPECT-CT

2014

7. European Society of Urologic Imaging, 6th European Multidisciplinary Meeting in Urologic Cancers, Lisbon, Portugal,

November 2014

Invited speaker: PET - CT in the Diagnostic of Renal Cell Carcinoma

8. European Society of Urologic Imaging, 6th European Multidisciplinary Meeting in Urologic Cancers, Lisbon, Portugal,

November 2014

Invited speaker: Is PET-CT playing an indispensable role in the management of urological malignancies

9. Iranian Heart Association, 2nd International Joint Congress, Tehran, Iran, February 2014

Invited speaker: Hybrid PET/CT imaging of the Hearth: Translation to PET/MRI

10. Austrian Society of Nuclear Medicine & Molecular Imaging, 31th International Symposium, Zell am See, Austria,

January 2014

Invited speaker: PET/CT Imaging in the Diagnosis of Prostate Cancer

2013

11. Austrian Society of Nuclear Medicine & Molecular Imaging, Zell am See, Austria, January 2013

Invited speaker: Choline PET – CT in Restaging of prostate cancer patients

16

12. International Nuclear Medicine Congress, May 2013, Shiraz, Iran

2013, invited speaker: Diagnosis of Neuroendocrine Tumors with Nuclear Medicine Procedures

13. International Nuclear Medicine Congress, May 2013, Shiraz, Iran

2013, invited speaker: Interactive Session, PET/CT in the Diagnosis of Neuroendocrine Tumors

Kongresstage Radiologie – Nuklearmedizin, 26 – 27 April 2013, Linz, Austria

Invited Speaker: Nuklearmedizin bei neuroendokrinen Tumoren und nuklearmedizinischen Therapiemöglichkeiten

2012

14. European Association of Nuclear Medicine; annual meeting, Milan, Italy, October 2012

Invited Speaker (CME Session), Diagnosis of Medullary Thyroid Cancer and Neuroendocrine Tumors with Nuclear

Medicine Procedures

15. European Association of Nuclear Medicine; annual meeting, Milan, Italy, October 2012

18F PMPA (BAY 1075553) PET/CT in staging and re-staging of prostate cancer patients - Phase I study and comparison to

18F FCH

16. American Society of Nuclear Medicine, 59th annual meeting, Vancouver, Canada, June 2012

F-18 fluorocholine PET/CT in the assessment of recurrent prostate cancer: correlation with PSA level

17. American Society of Nuclear Medicine, 59th annual meeting, Vancouver, Canada, June 2012

BAY 1075553 (18F PMPA) PET/CT in staging and re-staging of prostate cancer patients - Phase I study and comparison to

18F-FCH

18. Asian Ocean Federation of Nuclear Medicine & Biology Congress, Tehran, Iran, May 2012

Invited Speaker (CME Session): FCH- and Fluoride PET – CT in the assessment of bone metastases in prostate

cancer patients

2011

19. European Society of Radiology & European Association of Nuclear Medicine Joint Workshop, March 2011,

invited speaker: Future Aspects: Tracer Beyond FDG in Daily Routine

20. Thyroid symposium, Linz, Austria: April 2011, Invited speaker: PET – CT in the diagnosis of DTC & MTC

2010

21. American Society of Nuclear Medicine, 57th annual meeting, Salt Lake City, USA, June 2010, invited speaker

“Prostate Cancer Session” (CME): PET - CT imaging of prostate cancer with choline

22. European Association of Nuclear Medicine; annual meeting, October 2010, Value of 18F-Choline PET/CT in

restaging of prostate cancer patients with biochemical recurrence

23. European Association of Nuclear Medicine & European Society of Radiology Joint Workshop, October 2010,

invited speaker: Future Aspects: Tracer Beyond FDG in Daily Routine

17

24. European Association of Nuclear Medicine; annual meeting, October 2010, Invited speaker (CME) : Pitfalls,

Artifacts, Physiology: Tracers Beyond FDG,FCH & Fluoride

25. Iranian Society of Nuclear Medicine, annual meeting 2010, November 2010: Invited speaker (CME): Tracers Beyond

FCH in Prostate Cancer

2009

26. American Society of Nuclear Medicine, 56th annual meeting, Toronto, Canada, June 2009, F-18 Choline PET – CT in

preoperative staging of prostate cancer: experience of 130 intermediate - and high-risk patients

27. American Society of Nuclear Medicine, 56th annual meeting, Toronto, Canada, June 2009, Co-organizer & invited

speaker “Prostate Cancer Session” (CME): FCH- and Fluoride PET – CT in the assessment of bone metastases in

prostate cancer patients

28. American Society of Nuclear Medicine, 56th annual meeting, Toronto, Canada, June 2009, invited speaker “Prostate

Cancer Session” (CME): Fluoride PET – CT in the assessment of bone metastases in prostate cancer patients

2008

29. Department of Nuclear Medicine and Cardiology, St. Vincent’s Hospital Linz. May 2008. Clinical applications of PET

in the cardiology

30. American Society of Nuclear Medicine; 55th annual meeting, June 2008. New Orleans, USA. Assessment of malignant

and benign bone lesions by static F-18 Fluoride PET-CT: Additional value of SUV!

31. Department of Nuclear Medicine. St. Vincent’s Hospital Linz. November 2008. Onkologische PET - CT Diagnostik:

Indikationen, Durchführung und Fallberichte.

32. Department of Cardiology, St. Vincent’s Hospital Linz. April 2008. Assessment of myocardial viability by means of

nuclear imaging modalities, SPECT & PET.

2007

33. Department of Cardiology, St. Vinecent’s Hospital Linz. April 2007. Myocardial perfusion scintigraphy. Technical

aspects.

34. American Society of Nuclear Medicine; 54th annual meeting, June 2007. Washington, USA. Preoperative prostate cancer

staging with Fluor Coline (FCH) PET-CT.

35. American Society of Nuclear Medicine; 54th annual meeting, June 2007. Washington, USA. Comparison of F-18 Fluor

Choline PET/CT with F-18 Fluoride PET/CT in the detection of bone metastases in patients with prostate cancer.

36. American Society of Nuclear Medicine; 54th annual meeting, June 2007. Washington, USA. Potential value of F-18 Fluor

Choline in detection of bone metastases in patients with prostate cancer.

37. European Association of Nuclear Medicine; annual meeting, October 2007. Copenhagen, Denmark. Scintigraphic

follow-up of total knee endoprosthesis: A quantitative approach to the analysis of 3 phases bone scan.

18

38. European Association of Nuclear Medicine; annual meeting, October 2007. Copenhagen, Denmark. Influence of

hormone therapy in assessment of bone metastases in prostate cancer by means of F-18 Choline PET-CT.

39. European Association of Nuclear Medicine; annual meeting, October 2007. Copenhagen, Denmark. Scintigraphic

follow-up of total knee endoprosthesis: A quantitative approach to the analysis of 3 phases bone scan.

40. Department of Cardiology, St. Vincent’s Hospital Linz. December 2007. Prognostic value of myocardial perfusion

scintigraphy, comparison with other cardiac imaging modalities.

41. American Society of Nuclear Medicine; 53rd annual meeting, June 2006. San Diego, USA. Comparison of 18 F – DOPA

PET/CT with 18 F – FDG PET/CT for preoperative assessment and follow – up in patients with medullary thyroid

carcinoma.

2006

42. American Society of Nuclear Medicine; 53rd annual meeting, June 2006. San Diego, USA. Dynamic Acquisition of F –

18 DOPA PET – CT in Assessment of Different Subgroups of Neuroendocrine Tumors: Preliminary Results.

43. European Association of Nuclear Medicine; annual meeting, October 2006. Athens, Greece. The potential value of F –

18 FDG PET/CT versus conventional imaging modalities in preoperative staging of breast cancer.

44. European Association of Nuclear Medicine; annual meeting, October 2006. Athens, Greece. Assessment of medullary

thyroid carcinoma with F – 18 FOPA PET/CT in comparison to F – 18 FDG PET/CT.

45. European Association of Nuclear Medicine; annual meeting, October 2006. Athens, Greece. Preliminary results of

dynamic acquisition of F – 18 DOPA PET/CT in the assessment of neuroendocrine tumours: more diagnostic

information?

46. European Association of Nuclear Medicine; annual meeting, October 2006. Athens, Greece. Assessment of bone

metastases in patients with prostate cancer by dual – phase F – 18 Fluor Choline PET/CT.

47. Department of Cardiology, St. Vincent’s Hospital Linz. November 2006. Myocardial perfusion scintigraphy. Clinical

aspects.

48. European Association of Nuclear Medicine; annual meeting, October 2006. Athens, Greece.

F – 18 Fluor Choline PET/CT vs F – 18 Fluoride PET/CT in the detection of bone metastases in patients with prostate

cancer.

49. Iranian Society of Nuclear Medicine; 10th annual meeting, December 2006. Tehran, Iran. Potential value of FDG PET

in monitoring chemotherapy and radiotherapy of solid tumours.

50. Iranian Society of Nuclear Medicine; 10th annual meeting, December 2006. Tehran, Iran. Assessment of medullary

thyroid carcinoma with F-18 DOPA PET/CT in comparison to F-18 FDG PET-CT.

51. Oncological Colloquium of the Upper Austria. St. Vincent’s Hospital Linz. December 2006. Potential value of FDG

PET in monitoring chemotherapy and radiotherapy of solid tumours.

19

52. Iranian Society of Nuclear Medicine; 10th annual meeting, December 2006. Tehran, Iran. F – 18 Fluor Choline

PET/CT vs F – 18 Fluoride PET/CT in the detection of bone metastases in patients with prostate cancer.

2004

53. European Association of Nuclear Medicine; annual meeting, September 2004, Helsinki, Finland. Impact of Attenuation

Correction on the Interpretation of FDG Gamma Camera PET in the Assessment of Myocardial Viability.

54. European Association of Nuclear Medicine; annual meeting, September 2004. Helsinki, Finland. FDG Gamma Camera

PET Equipped with a 1 inch Crystal in Detection of Viable Myocardium: Comparison with dedicated PET and Tc-

Tetrofosmin.

55. European Association of Nuclear Medicine; annual meeting, September 2004. Helsinki, Finland. Comparison of

Whole-Body 18F-FDG PET and 11C-Acetate PET in the Detection of Metastatic Thyroid Cancer.

56. Iranian Society of Nuclear Medicine; 8th annual meeting, November 2004. Tehran, Iran. Iodine-123-Vascular

Endothelial Growth Factor-165 (123I-VEGF165): Biodistribution, Safety and Radiation Dosimetry in Patients with Pancreatic

Cancer.

57. Iranian Society of Nuclear Medicine; 8th annual meeting, November 2004. Tehran, Iran.Comparison of F-18

fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) with Computed Tomography (CT) /Magnetic

Resonance Imaging (MRI) for Follow-Up of the Patients with Gastrointestinal Stromal Tumor (GIST).

58. Iranian Society of Nuclear Medicine; annual meeting, December 2004. Tehran, Iran. Comparison of Tc-99m DPD

bone scanning and C-11 Acetate-PET in the assessment of bone involvement in prostate cancer.

2003

59. European Association of Nuclear Medicine; annual meeting, August 2003 of, Amsterdam, Netherlands. Comparison of

F-18 fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) with Computed Tomography (CT) /Magnetic

Resonance Imaging (MRI) for Follow-Up of the Patients with Gastrointestinal Stromal Tumor (GIST).

60. European Association of Nuclear Medicine; annual meeting, August 2003, Amsterdam, Netherlands. Assessment of

Cardiac viability with an improved coincidence gamma camera equipped with a 1 inch crystal.

20

ABSTRACTS

1. M. Beheshti, L. Imamovic, G. Spaun, M. Steinmair, K. Emmanuel, V. Alibegovic, C. Pirich, W. Langsteger

Value of 18F-Choline PET-CT in the assessment of primary hyperparathyroidism comparing with 99mTC-Sestamibi

SPECT-CT

Eur J Nucl Med Mol I 2015:OP 154 (Suppl. 2)

2. K. Akbari, S. Haim, K. Emmanuel, W. Zaglmair, C. Pirich, F. Fellner, W. Langsteger, M. Beheshti.

Value of FDG PET/CT in the assessment of patients with colon cancer comparing to stand-alone

Eur J Nucl Med Mol I 2015:P 679 (Suppl. 2)

3. C. C. Schiller, F. Fitz, S. Haim, H. Söser, J. Hochreiter, W. Langsteger, M. Beheshti.

Value of quantitative 3 - phase bone scintigraphy in the assessment of hip and knee endoprosthesis.

Eur J Nucl Med Mol I 2015:P 922 (Suppl. 2)

4. S. Haim, F. Fitzal, B. Saboury, A. Alavi, C. Schiller, W. Langsteger, M. Beheshti.

Semi-quantitative 18F-NaF PET/CT in the assessment of bone mineral density (BMD): Comparison with dual-energy

X-Ray Absorptiometry (DXA)

Eur J Nucl Med Mol I 2015:TP009 (Suppl. 2)

5. M Beheshti, S Zakavi, T. Kunit, R. Valencia, A.W. Stephens, L. M. Dinkelborg, W. Loidl,

W. Langsteger

“ PMPA (BAY 1075553) PET/CT in the detection of primary prostate cancer – Phase I study.”

J Nucl. Med. 2013:367 (Suppl. 2)

6. S. Haim, M. Beheshti, S. Zakavi, B. Saboury, M. Knauer, M. Steinmair, W. Langsteger, A. Alavi

„Semi-quantitative 18F- NaF-PET/CT in the assessment of bone mineral density: Comparison with dual energy x-ray

absorptiometry (DXA).”

J. Nucl. Med. 2013:480 (Suppl. 2)

7. W. Langsteger, W. Loidl, S. Haim, T. Kunit, R. Valencia, R. Lesche, L. Dinkelborg, S. Hinterhofer, M. Nader, M. Piert,

M. Beheshti

„Phase I Study: Bay 1075553 in Comparison with 18F-FCH PET/CT in Staging and Re- Staging of Prostate Cancer

Patients

Eur J Nucl Med Mol I 2012:255 (Suppl. 2)

8. M. Beheshti, R. Zakavi, S. Haim, M. Steinmeir, P. Waldenberger, I. Wolf, M. Nader, W. Loidl,

W. Langsteger

„The role of F-18 fluorocholine positron emission tomography/computed tomography in the management of patients

with prostate-specific antigen progression after radical treatment of prostate cancer: correlation with PSA levels“.


21

9. S. Haim, M. Beheshti, F. Fitz, E. Rechberger, M. Nader, P. Waldenberger, W. Saga, J. Hammer,

W. Langsteger

„Value of FDG PET/CT in the initial staging of breast cancer patients with locally advanced disease.“


10. M. Kohanpour, H. Rjabi, M. Beheshti, F. Kalantari, M. Pouladian

“Dual isotope cardiac imaging using TI-Tc cross-contamination correction by subtraction method.”


11. M Beheshti, I. Wolf, M. Steinmayer, G. Broinger, B. Kirchweger, M. Nader, W. Loidl, J. Hammer, W. Langsteger

„Value of 18F-Choline PET/CT in restaging of prostate cancer patients with biochemical recurrence”

Eur J Nucl Med Mol I 2010:270, (Suppl 2)

12. Beheshti M, Imamovic L, Broinger G, et al. F-18 Choline PET - CT in the preoperative staging of prostate cancer

patients with intermediate and high risk of extra - capsular disease: A prospective study in 130 patients.

J Nucl Med. 2009;50 (Suppl. 1)

13. Beheshti M, Vali R, Poecher S, Waldenberger P, Nader M, Fitz F, Fogelman I, Langsteger W. “Negative F-18 Fluoride

PET in malignant sclerotic bone lesions: Therapeutic effect, apoptosis, false negative?”

J Nucl Med. 2009;50 (Suppl. 1)

14. Beheshti M, Vali R, Poecher S, Waldenberger P, Nader M, Fitz F, Fogelman I, Langsteger W. “Negative F-18 Fluoride

PET in malignant sclerotic bone lesions: Therapeutic effect, apoptosis, false negative?”

J Nucl Med. 2008, 49 (Suppl 1):375P.

15. Beheshti M, Vali R, Waldenberger P, Fitz F, Immamovich L, Poecher S, Nader M, Fogelman I, Langsteger W. „F-18

Fluoride PET – CT in assessment of malignant and benign bone lesions: value of SUV, correlation with bone density by

Hounsfield Unit.”

Mol Imaging Biol 2008 (Supp 1).

16. Beheshti M, Vali R, Stoiber F, Nader M, Haim S, Jordanova N, Loidl W, Langsteger W. „Comparison of F-18 Fluor

Choline PET/CT with F-18 Fluoride PET/CT in the detection of bone metastases in patients with prostate cancer.”

J Nucl Med. 2007, 48 (Suppl 1):193P.

17. Beheshti M, Vali R, Fitz F, Haim S, Poecher S, Stoiber F, Nader M, Langsteger W. „Influence of hormone therapy in

assessment of bone metastases in prostate cancer by means of F-18 Choline PET-CT.”

Eur J Nucl Med Mol I. 2007, 34 (Suppl 2): S 122.

18. Beheshti M, Vali R, Nader M, Poecher S, Stoiber F, Fitz F, Loidl W, Langsteger W. “Potential value of F-18 Fluor

Choline in detection of bone metastases in patients with prostate cancer.”

J Nucl Med 2007, 48 (Suppl 1):193P.

22

19. Beheshti M, Poecher S, Heinisch M, Dirisamer A, Langsteger W. “Comparison of 18 F – DOPA PET/CT with 18 F

– FDG PET/CT for preoperative assessment and follow – up in patients with medullary thyroid carcinoma.”


20. Beheshti M, Dirisamer A, Haim S. Poecher S, Jordanova N, Fitz F, Nader M, Langsteger W. “Dynamic Acquisition of

F – 18 DOPA PET – CT in Assessment of Different Subgroups of Neuroendocrine Tumors: Preliminary Results.”


21. Beheshti M, Poecher S, Haim s, Jordanova N, Gruy B, Nader M, Fitz F, Langsteger W. “Assessment of medullary

thyroid carcinoma with F – 18 FOPA PET/CT in comparison to F – 18 FDG PET/CT.”

Eur J Nucl Med Mol I 2006, 33 (Suppl 2):131.

22. Beheshti M, Jordanova N, Poecher s, Haim S, Nader M, Fitz F, Langsteger W. „Preliminary results of dynamic

acquisition of F – 18 DOPA PET/CT in the assessment of neuroendocrine tumours: more diagnostic information?”


23. Beheshti M, Haim S, Nader m, Poecher S, Jordanova n, Stoiber F, Fitz F, Loidl W, Langsteger W. “Assessment of bone

metastases in patients with prostate cancer by dual – phase F – 18 Fluor Choline PET/CT.”


24. Beheshti M, Fitz F, Haim S, Nader M, Pocher S, Jordanova N, Stoiber F, Loidl W, Langsteger W. “F – 18 Fluor Choline

PET/CT vs F – 18 Fluoride PET/CT in the detection of bone metastases in patients with prostate cancer.”

Eur J Nucl Med Mol I 2006, 33 (Suppl 2):208-209.

25. Beheshti M, Dobrozemsky G, Khorsand A, Graf S, Oezer S, Ahmadzadehfar H, Dudczak R, Pirich C. “Impact of

Attenuation Correction on the Interpretation of FDG Gamma Camera PET in the Assessment of Myocardial Viability.”

Eur J Nucl Med Mol I 2004, 31 (Suppl 2):S320.

26. Beheshti M, Oezer S, Karanikas G, Li S, Dudczak R, Pirich C. “Comparison of Tc-99m DPD bone scanning and C-11

Acetate-PET in the assessment of bone involvement in prostate cancer.”

Iran J Nucl Med 2004, 8 :S38.

27. Beheshti M, Kletter K, Fueger B, Poetzi C, Schima W, Pirich C, Dudczak R, Li S. “Comparison of F-18


Resonance Imaging (MRI) for Follow-Up of the Patients with Gastrointestinal Stromal Tumor (GIST).”

Iran J Nucl Med 2004, 8 :S39.

28. Beheshti M, Peck M, Hamilton G, Preitfellner J, Graf S, Schima W, Anglberger P, Dudczak R, Li S. “Iodine-123-

Vascular Endothelial Growth Factor-165 (123I-VEGF165): Biodistribution, Safety and Radiation Dosimetry in Patients

with Pancreatic Cancer.”

Iran J Nucl Med 2004, 8:S40.

23

29. Beheshti M, Khorsand A, Graf S, Dobrozemsky G, Li S, Kletter K, Dudczak R, Pirich C. “FDG Gamma Camera PET

Equipped with a 1 inch Crystal in Detection of Viable Myocardium: Comparison with dedicated PET and Tc-

Tetrofosmin.”


30. Beheshti M, Kletter, K, Krcal K, Novotny C, Poetzi C, Schima W, Dudczak R, Li S. “Comparison of F-18


Resonance Imaging (MRI) for Follow-Up of the Patients with Gastrointestinal Stromal Tumor (GIST).”


31. Beheshti M, Dobrozemsky G, Khorsand A, Graf S, Dudczak R, Pirich C. “Assessment of Cardiac viability with an

improved coincidence gamma camera equipped with a 1 inch crystal.”

Eur J Nucl Med Mol Imaging 2003, 30 (Suppl 2):S152.

32. Vali R, Beheshti M, Waldenberger P, Fitz F, Haim S,Nader M, Fogelman I, Langsteger W. “Assessment of malignant

and benighn bone lesions by static F-18 Fluoride PET-CT: Additional value of SUV!”


33. Immamovic L, Beheshti M, Poecher S, Fitz F, Langsteger W. “Spontaneous psoas haematoma illustrated on Tc99 m

DPD bone scintigraphy in a patent with anticoagulation treatment.”

Wiener Klinische Wochenschrift, 2008, 15-16-

34. Imamovic L, Pöcher S, Beheshti M, Fitz F,Haim S, Langsteger W. „Kiefernekrose unter i.v. Biphosphonattherapie bei

Patientin mit ossär metastasiertem MTC.“

Nuklearmed 2008, accepted.

35. Poecher S, Beheshti M, Haim s, Fitz F, Poestelberger S, Langstegr W. “PET/CT with 18 F – fluorodeoxyglucose and

18 F – sodium fluoride in the detection of bone metastases: A comparison and description of discrepant results.”

Nuklearmed 2007, 44:A197.

36. Langsteger W, Beheshti M, Vali R, Poecher S, Haim S, Fitz F, Nader M, Sega W, Stoiber F, Loidl W. “Fluor CHoline

(FCH) PET-CT for preoperative prostate cancer staging.”

Eur J Nucl Med Mol I 2007, 34 (Suppl 2): S 122.

37. Haim S, Beheshti M, Vakil-Adli A, Fitz F, Poecher S, Vali R, Hochreiter J, Langsteger W. “Scintigraphic follow-up of

total knee endoprosthesis: A quantitative approach to the analysis of 3 phases bone scan.”

Eur J Nucl Med Mol I 2007, 34 (Suppl 2): S 177.

38. Langsteger W, Beheshti M, Fitz F, Vali R, Haim S, Jordanova N, Poecher S, Stoiber F, Loidl W. “Preoperative prostate

cancer staging with Fluor Coline (FCH) PET-CT.”


24

39. Haim S, Beheshti M, Fitz F, Jordanova N, Poecher S, Poestelberger S, Langsteger W. “The potential value of F – 18

FDG PET/CT versus conventional imaging modalities in preoperative staging of breast cancer.”


40. Langsteger W, Beheshti M, Nader M, Stoiber F, Loidl W, Dirisamer A, Poecher S, Haim S, Janetschek G. “Evaluation

of lymph node and bone metastases with Fluor Choline (FCH) PET – CT in the follow up of prostate cancer patients.”


41. Langsteger W, Beheshti M, W Loidl, Poecher S, Haim S, Nader M, Stoiber F, Janetschek G, Dirisamer A. “Fluor

Choline (FCH) PET – CT in preoperative staging of prostate cancer.”


42. Li S, Hossen A, Beheshti M, Peck M, Schmid M, Amir K, Dudczak R, Kletter K. “C11 Acetate PET, F18 FDG PET

and Ga67 citrate scintigraphy for visualization of hepatocellular carcinoma: a comparative study.”


43. Li S, Beheshti M, Peck M, Dudczak R, Kletter Kl. “Iodine-123-Vascular Endothelial Growth Factor-165 (123I-

VEGF165): Biodistribution, Safety and Radiation Dosimetry in Patients with Pancreatic Cancer.”

Nuklearmed 2004; 48:198-206.

44. Li S, Kienast O, Beheshti M, Oezer S, Pirich C, Kurtatran A, Becherer A, Kletter K, Dudczak R. “Comparison of

Whole-Body 18F-FDG PET and 11C-Acetate PET in the Detection of Metastatic Thyroid Cancer.”


45. Khorsand A, Beheshti M, Graf S, Kletter K, Porenta G, Dudczak R, Pirich C. “Comparison of Two Tracer Kinetic

Models for Assessment of Myocardial Perfusion with Dynamic N-13 Ammonia.”


46. Graf S, Khorsand A, Beheshti M, Dobrozemsky G, Wadsak W, Kletter K, Dudczak r, Porenta G, Pirich C. “FDG

Gamma Camera PET Equiped with 1 inch Crystal in Detection of Viable Myocardium: Comparison with dedicated PET

and Tc-Tetrofosmin.”

Eur J Nucl Med Mol I 2004, 31 (Suppl 2):S309-310.

47. Graf S, Beheshti M, Kienast O, Oezer S, Angelberger P, Dudczak R, Li S. “123I-Vascular Growth Factor (VEGF)

receptor scintigraphy in patients with coronary artery disease.”


48. Khorsand A, Graf S, Beheshti M, Porenta G, Pirich C. “Determination of myocardial blood flow by dynamic N-13

Ammonia: comparison of two methods of quantification.”


49. Khorsand A, Beheshti M, Graf S, Kletter K, Dudczak R, Porenta G, Pirich C. “Assessment of Left Ventricular Volumes

and Ejection Fraction Using ECG-Gated SPECT with 99mTechnetium-Tetrofosmin and FDG-PET.”

Nuklearmed 2003, 47: 123-124.

Documents

MOHSEN BEHESHTI MD - 2018ijcc.iha.org.ir2018ijcc.iha.org.ir/Files/7/Content/Dr_ Beheshti CV(2).pdf · curriculum vitae mohsen beheshti md febnm, fasnc phone +43 732 7677 7074 •